Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT01466036 2024-03-05

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 2 Completed

61 enrolled 9 charts

Endocrine

Carcinoid Tumor, Adenoma, Islet Cell, Neoplasm Metastasis

NCT04134390 2024-01-09

CABOMAYOR

Phase 2 Completed

25 enrolled

Genitourinary

Frailty, Carcinoma, Renal Cell

NCT01755195 2024-01-03

Cabozantinib for Adults With Advanced Soft Tissue Sarcoma

Phase 2 Completed

55 enrolled 16 charts

Sarcoma

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT03468985 2023-10-17

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Phase 2 Completed

3 enrolled 10 charts

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma

NCT02101736 2023-05-24

NF105-CABO

Phase 2 Completed

45 enrolled 10 charts

CNS

Neurofibromatoses, Neurofibroma, Plexiform

NCT03428217 2023-03-20

CANTATA

Phase 2 Completed

444 enrolled 15 charts

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04205799 2023-02-13

CABOCOL-01

Phase 2 Completed

57 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT01688999 2022-10-18

Cabozantinib for Advanced Urothelial Cancer

Phase 2 Completed

69 enrolled 14 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Urethral Neoplasms

NCT01835145 2022-08-04

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Phase 2 Completed

47 enrolled 12 charts

Dermatologic

Uveal Melanoma

NCT03542877 2022-07-15

Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer

Phase 2 Completed

44 enrolled 19 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT01630590 2022-03-25

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

Phase 2 Completed

62 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT03316586 2021-12-28

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Phase 2 Completed

18 enrolled 16 charts

Breast

Breast Neoplasms

NCT02216578 2021-07-15

Ph II CABOGIST in GIST

Phase 2 Completed

51 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02260531 2021-05-20

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Phase 2 Completed

36 enrolled 19 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03354884 2021-05-10

BONSAI

Phase 2 Completed

23 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT03463681 2021-04-26

BREAKPOINT

Phase 2 Completed

49 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT01835158 2021-02-11

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Phase 2 Completed

157 enrolled 10 charts 1 FDA

Genitourinary

Carcinoma, Renal Cell

NCT01588821 2020-09-29

Cabozantinib in Advanced Solid Malignancies

Phase 2 Completed

37 enrolled 10 charts

GenitourinaryThoracic

Lung Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Recurrence

NCT01599793 2020-03-26

Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

Phase 2 Completed

19 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT01716715 2020-03-10

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 2 Completed

111 enrolled 13 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02315430 2020-03-10

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

13 enrolled 11 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01866410 2019-05-16

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

37 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01834651 2017-09-27

A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases

Phase 2 Completed

17 enrolled 11 charts

Genitourinary

Prostatic Neoplasms

NCT01954745 2017-02-03

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

Phase 2 Completed

19 enrolled 8 charts

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT01738438 2016-12-06

Cabozantinib for Metastatic Triple Negative BrCa

Phase 2 Completed

35 enrolled 7 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

Clinical Trials

CABOTHYROID

CaboPoint

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

UNICAB

CABRAMET

IRCI Gynae Sarcomas, High Grade Uterine Sarcoma

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

CABATEN

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

ACTION

Cabozantinib and Nivolumab for Carcinoid Tumors

Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function

CaPture

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

PemCab

MERIDIAN

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

CABOMAYOR

Cabozantinib for Adults With Advanced Soft Tissue Sarcoma

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

NF105-CABO

CANTATA

CABOCOL-01

Cabozantinib for Advanced Urothelial Cancer

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Ph II CABOGIST in GIST

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

BONSAI

BREAKPOINT

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Cabozantinib in Advanced Solid Malignancies

Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer

A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

Cabozantinib for Metastatic Triple Negative BrCa